The role of antiangiogenic monoclonal antibodies combined to EGFR-TKIs in the treatment of advanced non-small cell lung cancer with activating EGFR mutations: acquired resistance mechanisms and strategies to overcome them  

作　　者：Danilo Rocco Luigi Della Gravara Giovanni Palazzolo Cesare Gridelli 

机构地区：[1]Department of Pulmonary Oncology,AORN dei Colli Monaldi,Naples 80131,Italy [2]Department of Experimental Medicine,Universitàdegli studi della Campania“Luigi Vanvitelli”,Naples 80138,Italy [3]UO Oncologia,“ULSS 6 Euganea”,Cittadella(PD)35131,Italy [4]Division of Medical Oncology,“S.G.Moscati”Hospital,Avellino 83100,Italy.

出　　处：《Cancer Drug Resistance》2022年第4期1016-1024,共9页癌症耐药（英文）

摘　　要：As of today, only two antiangiogenic monoclonal antibodies plus epidermal growth factor receptor-tyrosine kinaseinhibitor (EGFR-TKI) combinations are FDA and EMA-approved and are recommended by American Society ofClinical Oncology, European Society for Medical Oncology, and National Comprehensive Cancer Network for thefirst-line treatment of EGFR+ advanced non-small cell lung cancer patients: erlotinib plus bevacizumab anderlotinib plus ramucirumab. However, all treated patients eventually become unresponsive to such drugs, due toseveral different acquired resistance mechanisms, mainly represented by T790M substitutions and METamplifications. While osimertinib treatment in T790M+ patients still represents the only approved treatment,MET-TKIs will likely change this status quo in the near future. In fact, existing clinical data strongly support a rolefor MET-TKI-based combinations in EGFR+ MET-amplified patients, possibly revolutionizing our current treatmentalgorithm. Chemotherapy plus immunotherapy plus antiangiogenic therapy combinations could also representanother useful addition.

关 键 词：NSCLC EGFR T790M MET BEVACIZUMAB ramucirumab TKI resistance mechanisms 

分 类 号：R734.2[医药卫生—肿瘤]